Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | MLNR | O43193 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243579 | 0.87 | CHRM3 (0.55) | KMT2ACHRM3ALDH1A1CYP1A2CHRM1 | |
| SCHEMBL4247160 | 0.87 | CHRM3 (0.53) | KMT2ACHRM3ALDH1A1CYP1A2CHRM1 | |
| SCHEMBL13701451 | 0.86 | CHRM3 (0.70) | KMT2ACHRM3ALDH1A1CYP1A2CHRM1 | |
| SCHEMBL13701453 | 0.86 | CHRM3 (0.70) | KMT2ACHRM3ALDH1A1CYP1A2CHRM1 | |
| SCHEMBL4245324 | 0.86 | CHRM3 (0.70) | KMT2ACHRM3ALDH1A1CYP1A2CHRM1 | |
| SCHEMBL4241447 | 0.85 | CHRM3 (0.51) | KMT2ACHRM3ALDH1A1CYP1A2CHRM1 | |
| SCHEMBL13701472 | 0.84 | CHRM3 (0.75) | CHRM3CHRM1CHRM2HRH1HTR2B | |
| SCHEMBL17257485 | 0.84 | CHRM3 (0.45) | KMT2ACHRM3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4242514 | 0.84 | CHRM3 (0.50) | KMT2ACHRM3ALDH1A1CYP1A2CHRM1 | |
| SCHEMBL4242283 | 0.84 | CHRM3 (0.50) | KMT2ACHRM3ALDH1A1CYP1A2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-2013172-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007123465-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007123465-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | CHRM3, CHRM2, CHRM1 | KMT2A 1976/4885CHRM3 1/4885ALDH1A1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.